glofitamab + rituximab + ifosfamide + carboplatin + etoposide

This is a combination regimen comprising **glofitamab**, a bispecific monoclonal antibody targeting CD20 and CD3; **rituximab**, a monoclonal antibody targeting CD20; and the chemotherapeutic agents **ifosfamide** (alkylating agent), **carboplatin** (platinum-based alkylating agent), and **etoposide** (topoisomerase II inhibitor). Glofitamab engages T-cells (via CD3) to target and lyse malignant B-cells (expressing CD20), while rituximab mediates B-cell depletion through antibody-dependent and complement-mediated mechanisms. The chemotherapy agents cause cytotoxicity in rapidly dividing cells, contributing to their anti-lymphoma effects. This combination is being investigated for relapsed or refractory diffuse large B-cell lymphoma and other aggressive B-cell lymphomas, particularly after prior treatment failure[2][4][6][8].